Malignant melanoma is a highly aggressive disease, with minimal treatment options for patients that present in the later stages. In our Industry-Academia Partnerships and Pathways (IAPP) project, Target-Melanoma, we are investigating the molecular basis underlying this difficult-to-treat disease, focusing on the discovery of new biomarkers (i.e. indicators) or potential targets for therapy.
Target Melanoma was a four year project that came to an end in 2013. The SYS-MEL project is continuing some of the work established under this successful project.